|
Tissue Genesis’ Business
Tissue Genesis, Inc. seeks to advance tissue engineering
and cell therapy solutions that save lives and improve
the quality of life for patients with illness and disease.
Tissue Genesis’ business strategy is to promote the use
of a patients own adipose (fat) derived therapeutic cells
in repairing damaged tissue and coating of implants. These
cells can be delivered in a wound dressing, or can be
delivered to damaged tissue by means of a catheter or
direct injection, such as injection into damaged heart
tissue. These therapeutic cells can also be coated onto
implants, such as vascular grafts and stents. In addition
to enabling these applications through its intellectual
property, Tissue Genesis will manufacture operating room
systems for the derivation of these cells from the patient’s
adipose tissue during a medical procedure, leveraging
the company’s versatile enabling platform technology,
to add to the value chain for customers and their patients.
Both our systems and these specific applications represent
significant potential revenue streams for TGI.
Tissue Genesis was incorporated in the State of Hawaii
in 2001 by founders Anton Krucky, Thomas Cannon and
Bill Wiesmann, M.D. The company currently has 25 full
time employees, including a team of five PhDs who conduct
top tier research and development in bioengineering,
vascular tissue engineering, musculoskeletal tissue
engineering, cell therapy, and related regenerative
medicine fields. In 2003, Tissue Genesis built a world
class research facility in the newly developed Kaka‘ako
Biomedical Park, site of the University of Hawaii’s
new John A. Burns School of Medicine. Tissue Genesis’
facilities include office space; a 4200 square-foot
Class A wet lab, and a 3200 square-foot pre-manufacturing
area. Tissue Genesis is located in Honolulu, Hawaii
and our website address is www.tissuegenesis.com.
|
|
Mission
Tissue Genesis, Inc. is an emerging high-growth company
in the field of regenerative medicine, using a patient’s
own therapeutic cells to coat implants, repair damaged
tissue, heal disease, and other uses. Tissue Genesis
is leveraging its perfusion platform and expertise to
deliver products to the tissue engineering market. Current
near term applications include vascular grafts and wound
healing using patients’ own regenerative cells.
Highlights
| Founded: |
In 2001, began operations
2002 |
| Employees: |
25 with five PhDs |
| Lead Products: |
Vascular Conduit Solutions, Wound
Healing, Tissue Repair, BOS® Product Line |
| Intellectual
Property: |
| Derivation
and Use of Fat-Derived Autologous (Patient’s
Own)Therapeutic Cells |
|
Exclusive license of Dr.
Stuart Williams’ pioneering patent portfolio
from Thomas Jefferson University. |
| Connective
Tissue Engineering |
|
Exclusive license of Dr.
Paul Kosnik’s patent portfolio from University
of Michigan. |
| Bio-Optimization
System (BOS) Line of Products |
|
Patent applications pending. |
| Sustained
Pressure Sodding of Implants Using Therapeutic
Cells |
|
Developed at Tissue Genesis
– patents pending on advanced cell deposition
technology and hardware. |
|
| Ownership: |
Privately Held |
| Funding: |
Capital Investment, Contracts and
Grants |
| |
|
Tissue Genesis, Inc. Product and Company Overview |
|
